LEGN
Legend Biotech Corporation
NASDAQ · Healthcare · Biotechnology · US
$21.57
−0.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.0B | 627.2M | 285.1M | 117.0M |
| Cost of Revenue | 552.1M | 408.1M | 234.6M | 144.2M | 65.4M |
| Gross Profit | 719.2M | 620.8M | 392.7M | 140.9M | 51.6M |
| Operating Expenses | |||||
| R&D Expense | 396.4M | 414.7M | 413.5M | 382.2M | 335.6M |
| SG&A Expense | 375.0M | 341.6M | 284.3M | 200.9M | 174.0M |
| General & Admin Expense | 144.7M | 135.8M | 136.8M | 106.8M | 80.6M |
| Selling & Marketing Expense | 230.3M | 205.8M | 147.5M | 94.2M | 93.4M |
| Other Expenses | 4.2M | 1.0M | (1.9M) | (2.7M) | (2.4M) |
| Total Operating Expenses | 775.4M | 757.3M | 695.9M | 580.4M | 507.3M |
| Cost and Expenses | 1.3B | 1.2B | 930.5M | 724.6M | 572.6M |
| Operating Income (EBIT) | (56.2M) | (136.5M) | (303.2M) | (439.5M) | (455.6M) |
| Non-Operating | |||||
| Interest Income | 24.9M | 40.1M | 61.2M | 54.5M | 8.2M |
| Interest Expense | 16.8M | 21.4M | 21.6M | 21.8M | 10.8M |
| Net Interest Income | 8.1M | 18.7M | 39.6M | 32.7M | (2.6M) |
| Other Non-Op Income/Expense | (118.0K) | (146.1M) | 145.1M | (80.6M) | 9.9M |
| Non-Operating Income (excl Interest) | (13.1M) | 124.7M | (166.7M) | 58.8M | (20.7M) |
| EBT (Pre-Tax Income) | (56.3M) | (282.6M) | (158.1M) | (520.1M) | (445.7M) |
| Income Tax Expense | 35.3M | 14.2M | 18.9M | (1.9M) | 625.0K |
| Bottom Line | |||||
| Net Income | (91.6M) | (296.8M) | (177.0M) | (518.3M) | (446.3M) |
| Earnings from Cont. Ops | (91.6M) | (296.8M) | (177.0M) | (518.3M) | (446.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (91.6M) | (296.8M) | (177.0M) | (518.3M) | (446.3M) |
| Per Share | |||||
| Basic EPS | ($0.50) | ($1.60) | ($0.97) | ($2.94) | ($2.81) |
| Diluted EPS | ($0.51) | ($1.60) | ($0.97) | ($2.94) | ($2.81) |
| Revenue Per Share | $6.80 | $5.58 | $3.43 | $1.62 | $0.74 |
| Shares | |||||
| Basic Shares Outstanding | 187.0M | 184.3M | 182.9M | 176.1M | 159.0M |
| Diluted Shares Outstanding | 193.8M | 184.3M | 182.9M | 176.1M | 159.0M |
| Profitability Metrics | |||||
| EBITDA | (7.2M) | (232.3M) | (113.2M) | (477.9M) | (416.5M) |
| D&A | 35.8M | 28.9M | 23.4M | 20.5M | 18.4M |
| EBIT | (43.1M) | (261.2M) | (136.5M) | (498.3M) | (434.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026